PMID- 8648386
OWN - NLM
STAT- MEDLINE
DCOM- 19960725
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 14
IP  - 4
DP  - 1996 Apr
TI  - Allogeneic bone marrow transplant is not better than autologous transplant for 
      patients with relapsed Hodgkin's disease. European Group for Blood and Bone 
      Marrow Transplantation.
PG  - 1291-6
AB  - PURPOSE: To compare the results achieved with myeloablative therapy followed by 
      either allogeneic bone marrow transplantation (alloBMT) or autologous bone marrow 
      transplantation (ABMT) for patients with Hodgkin's disease (HD). PATIENTS AND 
      METHODS: Of more than 1,200 patients with HD reported to the European Bone Marrow 
      Transplantation (EBMT) registry, 49 underwent alloBMT. Of these, 45 with 
      sufficient data were matched to 45 patients who underwent ABMT. The matching 
      criteria were sex, age at time of transplantation, stage of disease at diagnosis, 
      bone marrow involvement at diagnosis and at transplantation, year of 
      transplantation, disease status at time of transplantation, time from diagnosis 
      to transplantation, and conditioning regimen with or without total-body 
      irradiation (TBI). RESULTS: The 4-year actuarial probabilities of survival, 
      progression-free survival (PFS), relapse, and non-relapse mortality were 25%, 
      15%, 61%, and 48% and 37%, 24%, 61%, and 27% after alloBMT and ABMT, 
      respectively. The toxic death rate at 4 years was significantly higher for 
      alloBMT patients (P = .04). For patients with sensitive disease at the time of 
      transplantation, the 4-year actuarial probability of survival was 30% after 
      alloBMT and 64% after ABMT (P = .007). This difference is mainly due to a higher 
      transplant-related mortality rate after alloBMT (65% v 12%, P = .005). Acute 
      graft-versus-host disease (aGVHD) > or = grade II was associated with a 
      significantly lower risk of relapse, but also with a lower overall survival (OS) 
      rate. CONCLUSION: Based on this study, alloBMT from a human leukocyte antigen 
      (HLA)-identical sibling donor does not appear to offer any advantage when 
      compared with ABMT. A graft-versus-Hodgkin effect is associated with > or = grade 
      II aGVHD, but its positive effect on relapse is largely offset by its toxicity. 
      In most circumstances, alloBMT cannot be recommended for patients with HD.
FAU - Milpied, N
AU  - Milpied N
AD  - Service d'Hematologie, Centre Hospitalier Universitaire, Nantes, France.
FAU - Fielding, A K
AU  - Fielding AK
FAU - Pearce, R M
AU  - Pearce RM
FAU - Ernst, P
AU  - Ernst P
FAU - Goldstone, A H
AU  - Goldstone AH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bone Marrow Transplantation/*methods
MH  - Case-Control Studies
MH  - Europe
MH  - Female
MH  - Graft vs Host Disease
MH  - Hodgkin Disease/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Probability
MH  - Proportional Hazards Models
MH  - Survival Analysis
MH  - Transplantation, Autologous
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
AID - 10.1200/JCO.1996.14.4.1291 [doi]
PST - ppublish
SO  - J Clin Oncol. 1996 Apr;14(4):1291-6. doi: 10.1200/JCO.1996.14.4.1291.